Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue
Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue
To assess the efficacy and safety of Pharmaton? PHL 00749 in improving cognitive function and
 allevi ating mental and physical stress in healthy male and female subjects leading demanding
 lifestyles.
This is a double-blind, placebo-controlled, randomised, parallel group trial in healthy male
 and fem ale subjects in regular employment. The duration of dosing will be 28 '(+/- 1)' days
 and assessments w ill be made on two visits (visits 2 and 3) with a training on the CDR
 system at the screening visit.

 The subjects will receive one bottle with 35 tablets [of either Ginseng G115 40 mg,
 multivitamin, mu ltimineral '+' Paullinia cupana extract PC102 75 mg (Guarana) or placebo]
 from the pharmacy at the in vestigational site. The subjects should take the study drug from
 day 0 to day 28 '(+/- 1)' Subjects will be assigned to one of the two treatment groups
 randomly. The allocation ratio is 2:1..

 Study Hypothesis:

 H0: No difference exists between the treatment and the placebo groups in terms o f
 baseline-adjusted change in Power of Attention after 28 days and averaged over 4 and 6 hour
 time point. H1: A difference exists between the treatment and the placebo groups in terms of
 baseline-adjusted change in Power of Attention after 28 days and averaged over 4 and 6 hour
 time point. The null and alternative hypotheses for the secondary endpoints are set up accor
 dingly. The statistical testing will be carried out at the 0.05 level of signifi cance. The
 test will be performed two-tailed.

 Comparison(s):

 The comparator is a matching placebo film-coated tablet without active ingredien ts.
INCLUSION CRITERIA Healthy male and female subjects in regular employment, aged between 20
 and 50 y ears. Subjects who give written informed consent in accordance with GCP and local
 legi slation.

 EXCLUSION CRITERIA Subjects who present with clinical depression. Subjects showing evidence
 of dementia. Clinically relevant abnormalities in medical history or examination. Subjects
 who have participated in a clinical study within 3 months prior to the start of the study.
 History of drug and/or alcohol abuse. Subjects who smoke more than 10 cigarettes per day.
 Subjects who in the opinion of the Investigator are heavy users of other tobacco or
 nicotine products (e.g. snuff, chewing tobacco, nicotine patches, nicotine g um, etc.).
 Subjects who have a history of food and/or drug allergies relevant to the study compound.
 Clinically relevant deviation from normal of any finding during pre-study medica l
 screening. Subjects who are unable to perform the cognitive tests. Subjects currently
 taking a cognition enhancing substance, including any Ginkgo, ginseng or guarana product.
 Any subject regularly taking a medication who might stop doing so at some time d uring the
 active dosing phase. Pregnant or lactating women or female subjects of child-bearing
 potential not us ing adequate means of birth control (condoms, contraceptive pills, IUDs,
 sterili sation). Subjects already taking other multi-vitamin products during the last 2
 weeks. Healthy subjects who are regularly taking drugs which act on the Central Nervous
 System (CNS).